Blair William & Co. IL Decreases Stock Holdings in Gilead Sciences, Inc. $GILD

Blair William & Co. IL lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 386,347 shares of the biopharmaceutical company’s stock after selling 11,908 shares during the period. Blair William & Co. IL’s holdings in Gilead Sciences were worth $42,834,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its position in Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the period. Nuveen LLC bought a new stake in Gilead Sciences in the first quarter worth about $620,415,000. Kingstone Capital Partners Texas LLC purchased a new position in Gilead Sciences in the second quarter valued at about $238,083,000. Los Angeles Capital Management LLC grew its position in shares of Gilead Sciences by 422.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after acquiring an additional 2,040,261 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the transaction, the insider owned 113,193 shares of the company’s stock, valued at $12,855,329.01. The trade was a 2.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. The trade was a 1.54% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,000 shares of company stock worth $9,402,130. 0.27% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages have weighed in on GILD. Rothschild & Co Redburn increased their price objective on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the company from $108.00 to $127.00 in a report on Friday, August 8th. UBS Group lifted their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Finally, Royal Bank Of Canada raised their price objective on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $118.08.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $116.74 on Friday. Gilead Sciences, Inc. has a 1-year low of $84.17 and a 1-year high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of $144.85 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The firm’s 50 day simple moving average is $114.57 and its 200 day simple moving average is $110.19.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the previous year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.